



For further information please contact:

ANTISENSE PHARMA GmbH
Ms. Ursula Dalferth / Public Relations
Josef-Engert-Str. 9 / D-93053 Regensburg
Phone ++49-941-92013-0 / Fax -29
e-mail: pr@antisense-pharma.com

Press Release

Antisense Pharma GmbH Raises 6.5 Million Euro in Ongoing Financing Round

REGENSBURG, GERMANY - November 27th, 2003. Antisense Pharma GmbH today announced that the company has secured 6.5 million EURO in first closing of the current financing round, including funding from existing investors, S-Refit AG and TBF, as well as from private investors. The German Global Chance Fund (GCF) signed an investment in a total of 3 million EURO.

This closing is the first step of Antisense Pharma's ongoing expansion financing. It ensures the clinical development of the company's lead product AP 12009 for the treatment of high-grade glioma, as well as bringing further promising drug candidates into the clinics.

Antisense Pharma GmbH is the leading European company in antisense therapeutics located in Regensburg, Germany. The company focuses on the development of novel antisense drugs for the treatment of malignant cancers.

This press release contains forward-looking statements with respect to the future business of Antisense Pharma GmbH. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that could occur in the future. There are a number of factors that could cause actual results and developments to differ materially. Antisense Pharma GmbH disclaims any intent or obligation to update any of these forward-looking statements.